Nova History
Find out the story behind the development of World's First Phyllanthus Niruri Standardized Extract
Incorporated Nova Laboratories Sdn. Bhd.
Commenced small scale R&D on Phyllanthus niruri, traditionally used for the treatment of liver diseases.
Received approval from National Pharmaceutical Regulatory Agency (NPRA) of the Ministry of Health (MOH) Malaysia to market and sell our Hepar-P Capsule.
Successfully developed and sold our own sustained-release glucosamine caplet in Malaysia
Awarded the Bionexus Status by Malaysian Biotechnology Corporation (MBC), now known as Malaysia Bioeconomy Development Corporation.
Granted a patent by Intellectual Property Corporation of Malaysia (MyIPO) for the herbal composition of Phyllanthus niruri extract used in our Hepar-P Capsule. Our Hepar-P Capsule was approved by Ministry of Health (MOH) Malaysia for use in government hospitals.
Developed the Actisof technology to enhance the absorption of oil-based ingredients, used in all our softgel products.
Granted another patent by Intellectual Property Corporation of Malaysia (MyIPO) for the standardized composition of Phyllanthus niruri extract used in our Hepar-P Capsule.
Appointed as an anchor company under the National Key Economic Areas (NKEA) Programme to develop ‘High-Value Herbal Products’ as part of the EPP1.
Completed the first clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
Pilot-scale trial of vegetable softgel from seaweed extract as an alternative to gelatin softgel.
Ready for the second clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
Successfully listed on the ACE market of Bursa Malaysia.